ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > 4 days

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Jun 03, 2021 6:47pm

99 Views

Post# 33326736

RE:4 days

With PMN and most Penny Stocks you will see a few Basis Points Increase or Decrease depending on a Positive or Negative Press Release. With PMN there has been a 90% YTD Increase.
If you look at the number of people Buying vs Selling you will notice we have been on a Upward Trend for the last 6 Months. PMN is asking for more Capital will definitely be around for Years to come. Look Long Term Buy and Hold for now. Cheers!

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks